Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.
Arthur Sands, Nurix Therapeutics CEO
June 8, 2026 06:57 AM EDT
DealsR&D
Reynald Castaneda
Deputy Editor
Roche stakes $700M on Nurix’s protein-degrading drug
Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T
Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying
Roche joins Californian Nurix oncology programme
隆基绿能：控股股东李振国解除质押1.55亿股-36氪
Roche fecha acordo de US$ 2,3 bilhões para remédio contra câncer
罗氏将向Nurix支付高达23亿美元的癌症药物交易款项-36氪
$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove…
(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental…
Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.
Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.
Roche pledges $700 million to join research on the drug bexobrutideg.
36氪获悉，隆基绿能公告，控股股东李振国将其原质押给国通信托的1.55亿股无限售流通股办理了解除质押手续，占其所持股份的14.52%。本次解除质押后，李振国累计质押公司股份2.1亿股，占其持股数量的19.68%。
